Sherif M, Wolfensberger T J
Jules Gonin Eye Hospital, University of Lausanne, Switzerland.
Klin Monbl Augenheilkd. 2017 Apr;234(4):501-504. doi: 10.1055/s-0042-122384. Epub 2017 Feb 1.
Proliferative vitreoretinopathy (PVR) occurs in 10 % of patients with retinal detachment and is characterized by excessive epi-, sub- or intraretinal contraction. Corticosteroids have been shown to counter this contraction. Retrospective review of 5 patients (3 females, 2 males) with recurrent retinal detachment with stage C PVR. The mean age was 61.2 ± 20.5 years and myopia > - 5.0 dioptres was present in 3 eyes. Patients were treated with 23 g vitrectomy, retinectomy and endolaser, dexamethasone (Ozurdex®) injection under perfluorocarbone and 5500 cs silicone oil tamponade. After a total follow-up of 8.8 ± 6.4 months with silicone oil tamponade, the Ozurdex® implant was localised in the macula in 1 case, and in 4 cases behind the iris with a completely attached retina. Preoperative intraocular pressure was 11.0 ± 4.0 mmHg, which remained stable at 7.8 ± 3.5 mmHg at the end of the final follow-up. No localised adverse effects were observed of the implant on the retina or the iris. The dexamethasone implant Ozurdex® is well tolerated in conjunction with silicone oil tamponade in eyes with retinal detachment and PVR. The implant may be a potential candidate for the prevention of PVR.
增殖性玻璃体视网膜病变(PVR)发生于10%的视网膜脱离患者中,其特征为视网膜表面、视网膜下或视网膜内过度收缩。已证实皮质类固醇可对抗这种收缩。对5例(3例女性,2例男性)复发性视网膜脱离伴C期PVR患者进行回顾性研究。平均年龄为61.2±20.5岁,3只眼存在近视度数>-5.0屈光度。患者接受了23g玻璃体切除术、视网膜切除术和眼内激光光凝,在全氟碳下注射地塞米松(Ozurdex®)并使用5500cs硅油填充。在硅油填充的总随访时间为8.8±6.4个月后,Ozurdex®植入物在1例中位于黄斑区,在4例中位于虹膜后方且视网膜完全复位。术前眼压为11.0±4.0mmHg,在末次随访结束时稳定在7.8±3.5mmHg。未观察到植入物对视网膜或虹膜的局部不良反应。地塞米松植入物Ozurdex®与硅油填充联合应用于视网膜脱离和PVR患者时耐受性良好。该植入物可能是预防PVR的潜在候选物。